• 1
    Miller RW, Young JL Jr., Novakovic B. Childhood cancer. Cancer. 1995; 75: 395405.
  • 2
    Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984; 224: 11211124.
  • 3
    Evans AE, Albo V, D'Angio GJ, et al. Factors influencing survival of children with nonmetastatic neuroblastoma. Cancer. 1976; 38: 661666.
  • 4
    Mora J, Cheung NK, Chen L, Qin J, Gerald W. Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer. 2001; 91: 435442.
  • 5
    Rubie H, Hartmann O, Michon J, et al. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 1997; 15: 11711182.
  • 6
    Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Engl J Med. 1985; 313: 11111116.
  • 7
    Matthay KK, Perez C, Seeger RC, et al. Successful treatment of Stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study. J Clin Oncol. 1998; 16: 12561264.
  • 8
    Rubie H, Michon J, Plantaz D, et al. Unresectable localized neuroblastoma: improved survival after primary chemotherapy including carboplatin-etoposide. Neuroblastoma Study Group of the Societe Francaise d'Oncologie Pediatrique (SFOP). Br J Cancer. 1998; 77: 23102317.
  • 9
    West DC, Shamberger RC, Macklis RM, et al. Stage III neuroblastoma over 1 year of age at diagnosis: improved survival with intensive multimodality therapy including multiple alkylating agents. J Clin Oncol. 1993; 11: 8490.
  • 10
    Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of Stages I and II neuroblastoma treated with surgery as primary therapy: a Children's Cancer Group study. J Clin Oncol. 2000; 18: 1826.
  • 11
    Hartmann O, Valteau-Couanet D, Vassal G, et al. Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant. 1999; 23: 789795.
  • 12
    Cheung NK, Heller G, Kushner BH, Burch L, O'Reilly RJ. Stage IV neuroblastoma more than 1 year of age at diagnosis: major response to chemotherapy and survival durations correlated strongly with dose intensity. Prog Clin Biol Res. 1991; 366: 567573.
  • 13
    August CS, Serota FT, Koch PA, et al. Treatment of advanced neuroblastoma with supralethal chemotherapy, radiation, and allogeneic or autologous bone marrow reconstitution. J Clin Oncol. 1984; 2: 609616.
  • 14
    Dini G, Philip T, Hartmann O, et al. Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant. 1989; 4(Suppl 4): 4246.
  • 15
    Dini G, Lanino E, Garaventa A, et al. Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol. 1991; 9: 962969.
  • 16
    Kushner BH, O'Reilly RJ, Mandell LR, Gulati SC, LaQuaglia M, Cheung NK. Myeloablative combination chemotherapy without total body irradiation for neuroblastoma. J Clin Oncol. 1991; 9: 274279.
  • 17
    Philip T, Zucker JM, Bernard JL, et al. Improved survival at 2 and 5 years in the LMCE1 unselected group of 72 children with Stage IV neuroblastoma older than 1 year of age at diagnosis: is cure possible in a small subgroup? J Clin Oncol. 1991; 9: 10371044.
  • 18
    Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr Clin North Am. 1991; 38: 393424.
  • 19
    Matthay KK, Atkinson JB, Stram DO, Selch M, Reynolds CP, Seeger RC. Patterns of relapse after autologous purged bone marrow transplantation for neuroblastoma: a Childrens Cancer Group pilot study. J Clin Oncol. 1993; 11: 22262233.
  • 20
    Evans AE, Silber JH, Shpilsky A, D'Angio GJ. Successful management of low-stage neuroblastoma without adjuvant therapies: a comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution. J Clin Oncol. 1996; 14: 25042510.
  • 21
    Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II Study. J Clin Oncol. 2002; 20: 22842292.
  • 22
    Cohn SL, Moss TJ, Hoover M, et al. Treatment of poor-risk neuroblastoma patients with high-dose chemotherapy and autologous peripheral stem cell rescue. Bone Marrow Transplant. 1997; 20: 543551.
  • 23
    Philip T, Ladenstein R, Lasset C, et al. 1070 Myeloablative megatherapy procedures followed by stem cell rescue for neuroblastoma: 17 years of European experience and conclusions. European Group for Blood and Marrow Transplant Registry Solid Tumour Working Party. Eur J Cancer. 1997; 33: 21302135.
  • 24
    Evans AE, August CS, Kamani N, et al. Bone marrow transplantation for high risk neuroblastoma at the Children's Hospital of Philadelphia: an update. Med Pediatr Oncol. 1994; 23: 323327.
  • 25
    Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341: 11651173.
  • 26
    Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993; 11: 14661477.
  • 27
    Vassal G, Deroussent A, Challine D, et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood. 1992; 79: 24752479.
  • 28
    National Cancer Institute. Common Toxicity Criteria manual. Washington, DC: National Cancer Institute, 1997.
  • 29
    Evans AE, D'Angio GJ, Koop CE. The role of multimodal therapy in patients with local and regional neuroblastoma. J Pediatr Surg. 1984; 19: 7780.
  • 30
    Matthay KK, O'Leary MC, Ramsay NK, et al. Role of myeloablative therapy in improved outcome for high risk neuroblastoma: review of recent Children's Cancer Group results. Eur J Cancer. 1995; 31A: 572575.
  • 31
    Cheung NV, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival, and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991; 9: 10501058.
  • 32
    Garaventa A, Boni L, Lo Piccolo MS, et al. Localized unresectable neuroblastoma: results of treatment based on clinical prognostic factors. Ann Oncol. 2002; 13: 956964.
  • 33
    Garaventa A, De Bernardi B, Pianca C, Donfrancesco A, Cordero di Montezemolo L. Localized but unresectable neuroblastoma: treatment and outcome of 145 cases. J Clin Oncol. 1993; 11: 17701779.
  • 34
    Hovi L, Saarinen-Pihkala UM, Vettenranta K, Lipsanen M, Tapanainen P. Growth in children with poor-risk neuroblastoma after regimens with or without total body irradiation in preparation for autologous bone marrow transplantation. Bone Marrow Transplant. 1999; 24: 11311136.
  • 35
    Teinturier C, Hartmann O, Valteau-Couanet D, Benhamou E, Bougneres PF. Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone Marrow Transplant. 1998; 22: 989994.
  • 36
    Matthay KK, Sather HN, Seeger RC, Haase GM, Hammond GD. Excellent outcome of Stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989; 7: 236244.
  • 37
    Castleberry RP, Kun LE, Shuster JJ, et al. Radiotherapy improves the outlook for patients older than 1 year with Pediatric Oncology Group Stage C neuroblastoma. J Clin Oncol. 1991; 9: 789795.
  • 38
    Haas-Kogan DA, Swift PS, Selch M, et al. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study. Int J Radiat Oncol Biol Phys. 2003; 56: 2839.
  • 39
    Bradfield SM, Douglas JG, Hawkins DS, Sanders JE, Park JR. Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma. Cancer. 2004; 100: 12681275.
  • 40
    Haas-Kogan DA, Fisch BM, Wara WM, et al. Intraoperative radiation therapy for high-risk pediatric neuroblastoma. Int J Radiat Oncol Biol Phys. 2000; 47: 985992.